Some evidence indicated that brentuximab vedotin could also bring clinical benefit to CD30-positive PTCL-NOS patients, not other subtypes of PTCL [18]. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.